Dexamethasone: Uses, Doses, Side Effects, and How It Compares to Other Corticosteroids

What Is Dexamethasone and How Does It Work?

Dexamethasone is a fluorinated synthetic glucocorticoid that binds the intracellular glucocorticoid receptor with high affinity, suppressing the transcription of pro-inflammatory cytokines including interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha. That receptor-binding affinity is approximately four times greater than that of prednisolone and roughly 30 times greater than cortisol itself. [1]

Once bound, the drug-receptor complex enters the nucleus and modulates hundreds of genes simultaneously. Anti-inflammatory effects appear within one to four hours of an oral or intravenous dose. The biologic half-life of 36 to 54 hours means a single morning dose suppresses the hypothalamic-pituitary-adrenal (HPA) axis for the entire day, making once-daily dosing sufficient for most indications. [2]

Fluorination at the 9-alpha position is what distinguishes dexamethasone from cortisol and prednisone. That structural change magnifies glucocorticoid potency while nearly abolishing mineralocorticoid activity (roughly 0 to 0.03 relative to fludrocortisone). Patients relying on dexamethasone for long-term adrenal replacement therefore need a separate mineralocorticoid, typically fludrocortisone (Florinef) 0.05 to 0.2 mg daily, to prevent dangerous sodium loss and hyperkalemia. [3]

FDA-Approved Indications: What Dexamethasone Is Prescribed For

The FDA label covers a wide set of conditions, organized across several categories. Inflammatory and allergic diseases include severe asthma, acute allergic reactions, contact dermatitis, and drug hypersensitivity. Autoimmune conditions include rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease flares. Oncology applications include brain metastasis-associated edema, hematologic malignancies, and chemotherapy-induced nausea prophylaxis. [4]

Neurologically, dexamethasone 10 mg IV followed by 4 mg every six hours is a standard regimen for reducing peritumoral edema. The dose is tapered as quickly as the clinical picture allows because higher cumulative glucocorticoid exposure accelerates bone loss and increases infection risk.

The drug also anchors two major diagnostic tests. The 1 mg overnight dexamethasone suppression test (DST) screens for Cushing syndrome: a morning serum cortisol below 1.8 mcg/dL after a midnight 1 mg oral dose makes hypercortisolism unlikely. The low-dose (2 mg/day x 2 days) and high-dose (8 mg/day x 2 days) DSTs help distinguish Cushing disease from ectopic ACTH secretion. The Endocrine Society's 2008 clinical practice guideline states: "We recommend the 1-mg overnight DST as an initial test for Cushing syndrome given its sensitivity of approximately 95% to 98%." [5]

The RECOVERY Trial: Dexamethasone and COVID-19

The most consequential modern use of dexamethasone emerged from the RECOVERY (Randomized Evaluation of COVID-19 Therapy) trial published in the New England Journal of Medicine in 2021. Among 6,425 hospitalized patients, dexamethasone 6 mg once daily for up to 10 days reduced 28-day all-cause mortality by 35% in ventilated patients (rate ratio 0.65; 95% CI 0.51-0.82) and by 18% in patients requiring supplemental oxygen only (rate ratio 0.82; 95% CI 0.72-0.94). [6] Patients who did not require respiratory support saw no mortality benefit and a possible trend toward harm, reinforcing that glucocorticoids blunt the hyperinflammatory phase of illness rather than the virus itself.

The NIH COVID-19 Treatment Guidelines adopted this evidence promptly, recommending dexamethasone 6 mg daily (IV or oral) for hospitalized patients requiring oxygen, with remdesivir and baricitinib added in certain subgroups. [7] That single trial changed ICU practice worldwide, cementing dexamethasone as the first drug proven to reduce COVID-19 mortality.

Dexamethasone vs. Prednisone vs. Prednisolone vs. Hydrocortisone: Potency Table

Choosing among corticosteroids depends on potency, duration of action, mineralocorticoid effect, and whether the patient can convert prodrugs. Prednisone is a prodrug converted to prednisolone by 11-beta-hydroxysteroid dehydrogenase in the liver. Patients with severe liver disease, infants, and some pregnant women absorb prednisolone more reliably because this conversion is intact. [8]

| Corticosteroid | Glucocorticoid Potency | Mineralocorticoid Potency | Biologic Half-Life | |---|---|---|---| | Hydrocortisone (Cortef) | 1 (reference) | 1 | 8-12 hours | | Prednisone | 4 | 0.8 | 18-36 hours | | Prednisolone | 4-5 | 0.8 | 18-36 hours | | Dexamethasone | 25-30 | ~0 | 36-54 hours | | Fludrocortisone (Florinef) | 10 | 125-150 | 18-36 hours |

Hydrocortisone (brand: Cortef) is the standard replacement choice for adrenal insufficiency because its mineralocorticoid activity most closely mimics physiologic cortisol. The Endocrine Society's 2016 guideline on adrenal insufficiency recommends hydrocortisone 15 to 25 mg per day in two to three divided doses, with the largest dose on waking. [9] Fludrocortisone 0.05 to 0.1 mg once daily is added for primary adrenal insufficiency (Addison disease) to replace aldosterone. [9]

Prednisone at 5 mg is roughly equivalent to 1.25 mg dexamethasone or 25 mg hydrocortisone. This conversion matters when switching routes or drugs during a stress dose situation.

The HealthRX Corticosteroid Selection Framework guides clinicians through three decision branches: (1) Is mineralocorticoid replacement needed? If yes, use hydrocortisone plus fludrocortisone, not dexamethasone. (2) Is once-daily convenience or HPA-axis suppression testing the goal? Dexamethasone is preferred. (3) Is the goal short-term anti-inflammatory therapy in a patient with intact liver function? Prednisone or prednisolone at equivalent doses will work, with prednisone generally preferred for adults and prednisolone for pediatric patients and those with hepatic dysfunction.

Dosing Dexamethasone: Oral, IV, and Intramuscular Routes

Oral bioavailability of dexamethasone tablets (0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg) reaches 70 to 80%. Peak plasma concentration occurs at one to two hours. The liquid concentrate (Dexamethasone Intensol, 1 mg/mL) offers flexibility for patients unable to swallow tablets. [4]

Common dose ranges by indication:

• Cerebral edema: 10 mg IV loading dose, then 4 mg IV/IM every 6 hours, tapered over 5-7 days.
• Croup (laryngotracheobronchitis): single dose 0.15-0.6 mg/kg orally or IM, max 10 mg.
• Chemotherapy-induced nausea: 8-20 mg IV 30 minutes before chemotherapy.
• COVID-19 (hospitalized, oxygen-requiring): 6 mg orally or IV once daily x 10 days.
• Cushing syndrome screening (overnight DST): 1 mg orally at 11 pm, serum cortisol drawn at 8 am.
• Altitude sickness (HACE): 8 mg initially, then 4 mg every 6 hours.
• Multiple myeloma (VRd regimen): 20-40 mg orally on days 1, 8, 15, 22 of a 28-day cycle.

Stress dosing (sick-day rules) is not typically required for short courses of fewer than 5 days at any dose. Patients on chronic supraphysiologic glucocorticoid therapy exceeding three weeks at doses above 5 mg prednisone equivalent may have HPA axis suppression and need stress-dose guidance from their prescriber before any surgical procedure or acute illness. [10]

Side Effects and Risks: What to Monitor

Short courses under five to seven days carry low risk of serious adverse effects. Longer or higher-dose courses produce a predictable set of complications tied to glucocorticoid receptor activation throughout the body. [11]

Metabolic effects. Dexamethasone raises blood glucose by stimulating hepatic gluconeogenesis and reducing peripheral insulin sensitivity. Even a single 10 mg IV dose can raise postprandial glucose by 100-150 mg/dL in patients with type 2 diabetes. Continuous glucose monitoring data suggest glucose spikes are highest in the afternoon, consistent with the drug's long biologic half-life.

Bone loss. Glucocorticoid-induced osteoporosis (GIOP) is the most common drug-induced form of osteoporosis. The American College of Rheumatology 2022 guideline recommends starting oral bisphosphonate therapy in adults who will take any glucocorticoid at a prednisone-equivalent dose of 2.5 mg or more per day for three or more months. [12] Calcium 1,000-1 to 200 mg and vitamin D 600-800 IU daily are standard co-prescriptions.

HPA axis suppression. Doses above 0.5 mg dexamethasone daily for more than two to three weeks suppress ACTH release. Abrupt discontinuation after prolonged therapy can precipitate adrenal crisis: nausea, hypotension, and severe fatigue. Tapering schedules must be individualized.

Neuropsychiatric effects. Mood disturbance, insomnia, and rarely frank psychosis can emerge, particularly at doses above 4 mg/day. These effects often resolve with dose reduction.

Ocular effects. Chronic use raises intraocular pressure and accelerates posterior subcapsular cataract formation.

Infection risk. Dexamethasone at immunosuppressive doses (equivalent to prednisone 20 mg or more for four or more weeks) warrants consideration of Pneumocystis jirovecii pneumonia (PJP) prophylaxis with trimethoprim-sulfamethoxazole. [13]

Dexamethasone vs. Fludrocortisone (Florinef): Different Jobs

These two steroids are often mentioned together but serve distinct purposes. Dexamethasone replaces or augments glucocorticoid activity. Fludrocortisone replaces mineralocorticoid (aldosterone) activity. Fludrocortisone at 0.1 mg has a mineralocorticoid potency 125 to 150 times that of hydrocortisone and only modest glucocorticoid activity. [14]

Patients with Addison disease need both. The standard regimen is hydrocortisone (not dexamethasone) plus fludrocortisone. Using dexamethasone as the glucocorticoid in Addison disease is possible but complicates dosing because its long half-life makes HPA monitoring difficult, and its zero mineralocorticoid activity makes fludrocortisone dosing more predictable by comparison. Some endocrinologists do use low-dose dexamethasone (0.25-0.5 mg at bedtime) in adrenal insufficiency patients who experience early-morning fatigue on hydrocortisone, leveraging its prolonged overnight action.

Patients with congenital adrenal hyperplasia (CAH) often receive dexamethasone at 0.25 mg at bedtime to suppress the nocturnal ACTH surge that drives androgen excess, per the Endocrine Society's 2018 CAH guideline. [15]

Fludrocortisone dosing is monitored via plasma renin activity (target high-normal), serum electrolytes, and blood pressure. Underdosing causes salt wasting; overdosing causes hypertension and hypokalemia.

Drug Interactions Worth Knowing

Several drug interactions change dexamethasone's exposure or its downstream effects. [16]

CYP3A4 inducers (rifampin, phenytoin, carbamazepine, phenobarbital) accelerate dexamethasone metabolism and can halve plasma levels, potentially precipitating adrenal insufficiency in replacement patients. Dose increases of 50 to 100% may be needed.

CYP3A4 inhibitors (itraconazole, ritonavir, clarithromycin) raise dexamethasone exposure and increase cushingoid side effects. Fluconazole at standard antifungal doses has produced iatrogenic Cushing syndrome in patients on inhaled or systemic corticosteroids.

Warfarin: glucocorticoids can both increase and decrease anticoagulant effect depending on the clinical context. INR should be monitored within one to two weeks of starting or stopping corticosteroids.

NSAIDs: combining dexamethasone with NSAIDs multiplies gastrointestinal mucosal injury risk roughly three- to fivefold. A proton pump inhibitor is appropriate when this combination is unavoidable.

Live vaccines are contraindicated in patients on immunosuppressive glucocorticoid doses (prednisone-equivalent 20 mg or more per day for two or more weeks). [17]

Monitoring Checklist for Patients on Long-Term Dexamethasone

For courses extending beyond four to six weeks, a structured monitoring plan reduces harm. [12, 18]

• Fasting glucose or HbA1c at baseline and every three months.
• Blood pressure at each clinic visit.
• Body weight monthly.
• DXA bone mineral density at baseline; repeat at 12 months.
• Ophthalmology referral after 12 months of therapy or sooner if visual symptoms develop.
• Electrolytes at baseline (though dexamethasone rarely disturbs sodium/potassium alone).
• Lipid panel at baseline; hyperlipidemia is common with doses above 5 mg prednisone equivalent.
• Morning cortisol or ACTH stimulation test before attempting taper after prolonged use.

The American Association of Clinical Endocrinology (AACE) notes that glucocorticoid-induced hyperglycemia often manifests as post-meal (postprandial) spikes rather than fasting hyperglycemia, so fasting glucose alone may miss the diagnosis. [18]

Special Populations

Pregnancy. Dexamethasone crosses the placenta because it is not deactivated by placental 11-beta-HSD2 (unlike prednisone, which is mostly inactivated before reaching the fetus). This property is intentional when fetal drug delivery is needed, as in congenital adrenal hyperplasia prenatal treatment or promotion of fetal lung maturity at 24 to 34 weeks gestation when betamethasone is unavailable. [19] For conditions affecting the mother only (such as autoimmune disease), prednisolone is preferred because less reaches the fetus.

Pediatrics. Weight-based dosing is standard. Dexamethasone suppresses growth velocity in children at doses above physiologic replacement, so the lowest effective dose and shortest duration are essential. Growth should be plotted at every visit.

Renal impairment. No dose adjustment is required for dexamethasone itself. However, fluid retention from concurrent mineralocorticoid effects of other steroids may worsen edema; this is rarely an issue with dexamethasone given its near-zero mineralocorticoid activity.

Hepatic impairment. Dexamethasone is an active drug (not a prodrug), so it does not require liver conversion the way prednisone does. It remains the preferred oral corticosteroid in severe hepatic dysfunction.